ADC Therapeutics SA filed an 8-K press release on November 3, 2026, announcing that Chief Executive Officer Ameet Mallik will participate in two investor conferences later in November 2026.

Key Highlights

  • Guggenheim conference: ADC Therapeutics is scheduled to present at the Guggenheim Third Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 1:30 p.m. EST in Boston, MA.
  • Jefferies conference: The company is also scheduled to present at the Jefferies Global Healthcare Conference on Thursday, November 19, 2026, at 1:00 to 1:25 p.m. GMT in London, England.
  • Format and speaker: Both presentations will be fireside chats with Ameet Mallik, Chief Executive Officer, as the speaker.
  • Webcast access: Live webcasts will be available on the Events and Presentations page at ir.adctherapeutics.com, with replays available for approximately 30 days following each event.
  • Exchange listing: ADC Therapeutics SA is listed on NYSE:ADCT and is headquartered in Lausanne (Biopole), Switzerland, with operations in New Jersey.

ADC Therapeutics Schedules CEO Fireside Chats at Guggenheim and Jefferies Events

According to the press release filed November 3, 2026, ADC Therapeutics SA (NYSE:ADCT) announced that its Chief Executive Officer, Ameet Mallik, will participate in two investor conferences during November 2026. The first is the Guggenheim Third Annual Healthcare Innovation Conference, scheduled for Tuesday, November 10, 2026, at 1:30 p.m. EST in Boston, MA. The second is the Jefferies Global Healthcare Conference, scheduled for Thursday, November 19, 2026, with a presentation time of 1:00 to 1:25 p.m. GMT in London, England. Both appearances are in a fireside chat format, the company disclosed.

The filing states that live webcasts of both presentations will be accessible through the Events and Presentations section of the company's investor relations website at ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event, according to the announcement.

ADC Therapeutics described itself in the filing as "a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)," with its commercial product ZYNLONTA (loncastuximab tesirine-lpyl) having received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The filing contains forward-looking statements, which the company cautioned are subject to risks and uncertainties as described in its regulatory filings.

What Was Disclosed

ADC Therapeutics announced CEO Ameet Mallik will appear in fireside chat sessions at the Guggenheim Third Annual Healthcare Innovation Conference on November 10, 2026, and the Jefferies Global Healthcare Conference on November 19, 2026, with live webcasts available to the public.